Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer
Autore:
Heidenreich, A; von Knobloch, R; Hofmann, R;
Indirizzi:
Univ Marburg, Dept Urol, D-35043 Marburg, Germany Univ Marburg Marburg Germany D-35043 Dept Urol, D-35043 Marburg, Germany
Titolo Testata:
EUROPEAN UROLOGY
fascicolo: 2, volume: 39, anno: 2001,
pagine: 121 - 130
SICI:
0302-2838(200102)39:2<121:CSOCCI>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHASE-II TRIAL; ORAL ESTRAMUSTINE PHOSPHATE; SOUTHWEST-ONCOLOGY-GROUP; PALLIATIVE END-POINTS; TREATMENT-OF-CANCER; EUROPEAN-ORGANIZATION; MITOMYCIN-C; ANDROGEN-DEPRIVATION; WEEKLY DOXORUBICIN; PROGNOSTIC FACTORS;
Keywords:
androgen independence; estramustine; mitoxantrone; anthracyclines;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
64
Recensione:
Indirizzi per estratti:
Indirizzo: Heidenreich, A Univ Marburg, Dept Urol, Baldingerstr, D-35043 Marburg, Germany Univ Marburg Baldingerstr Marburg Germany D-35043 Germany
Citazione:
A. Heidenreich et al., "Current status of cytotoxic chemotherapy in hormone refractory prostate cancer", EUR UROL, 39(2), 2001, pp. 121-130

Abstract

Adenocarcinoma of the prostate is the most prevalent neoplastic disease inmen and continues to be a major cause of morbidity and mortality. Death from prostate cancer is associated with objective and biochemical progressionfollowing hormonal manipulations often described as hormone refractory prostate cancer (HRPCA). Therapy for HRPCA is primarily palliative and therapeutic efficacy has to be balanced against potential treatment-related side effects. Therapeutic efficacy may be assessed by evaluating the percentage of patients obtaining a PSA decline of >50%, evaluating the response of bidimensionally measurable disease or by improvements in quality of life assessments. The most effective cytotoxic therapies at the present time seem to be combinations of estramustine phosphate with taxanes and etoposide. Regimes employing ketoconazole with estramustine, vinblastine or bisphosphonates seem to be worthy of further evaluation. Mitoxantrone has an impressive palliative effect in patients, particularly when combined with hydrocortisone. Oral chemotherapeutic regimens with a combination of estramustine phosphate, cyclophosphamide and prednisone appear to offer a less toxic alternative. For the future we need prospective randomized clinical phase-III studies,prognosticators identifying patients as being at high or low risk who might benefit from different therapeutic approaches and generally binding eligibility and response guidelines in order to be able to compare trials of different therapeutic approaches. Copyright (C) 2001 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 07:18:31